Virus injection takes on tough tumors in early trial

NCT ID NCT06368921

Recruiting now Disease control Sponsor: Guangzhou Virotech Pharmaceutical Co., Ltd. Source: ClinicalTrials.gov ↗

First seen Jan 08, 2026 · Last updated May 24, 2026 · Updated 21 times

Summary

This early-phase study tests a modified virus called VRT106 that is injected directly into tumors to see if it is safe and can shrink cancers. About 30 adults with advanced solid tumors that have not responded to standard treatments will receive the virus. The main goal is to find the best dose and check for side effects.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for SOLID TUMOR are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Affiliated Cancer Hospital of Shandong First Medical University
RECRUITING

Jinan, Shandong, China

Contact
Affiliated Cancer Hospital of Zhengzhou University
RECRUITING

Zhengzhou, Henan, China

Contact
Sun Yat-sen University Cancer Center
RECRUITING

Guangzhou, Guangdong, China

Contact Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.

SOLID TUMOR